Broncus Holding Corp. (HK:2216)
:2216
Want to see HK:2216 full AI Analyst Report?
Top Page
Broncus Holding Corp.
(2216)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$1.00
▼(-57.63% Downside)
Action:ReiteratedDate:04/23/26
The score is held down primarily by very weak operating performance (sharp revenue decline, continued large losses) and ongoing cash burn, only partly offset by a low-leverage balance sheet with positive equity. Technicals also remain soft with the stock trading below major moving averages and negative MACD, while valuation provides limited support due to a loss-making negative P/E and no dividend data.
Positive Factors
Low Leverage / Strong Equity
Extremely low leverage and sizable positive equity materially reduce refinancing risk and provide durable financial flexibility. This balance-sheet strength gives the company a runway to fund operations, R&D or restructuring and absorb operating volatility over several months.
Negative Factors
Severe Revenue Collapse
A ~97% YoY revenue decline reflects catastrophic loss of commercial traction and scale. Such a collapse undermines pricing power, channel relationships and cost absorption. Restoring meaningful revenue will likely require multiple quarters of execution and constrains durable profitability prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Equity
Extremely low leverage and sizable positive equity materially reduce refinancing risk and provide durable financial flexibility. This balance-sheet strength gives the company a runway to fund operations, R&D or restructuring and absorb operating volatility over several months.
Read all positive factors
Broncus Holding Corp. (2216) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$655.63M
Dividend YieldN/A
Average Volume (3M)2.03M
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth-30.60%
EPS Growth28.61%
CountryHK
Employees200
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding528,737,060
10 Day Avg. Volume1,907,700
30 Day Avg. Volume2,030,864
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.99
Price to Sales (P/S)848.76
P/FCF Ratio-14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$16.96M
Broncus Holding Corp. Business Overview & Revenue Model
Company Description
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such ...
Broncus Holding Corp. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
23
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 174.26K | 8.13M | 10.26M | 9.41M | 10.89M |
| Gross Profit | -2.76M | 6.14M | 7.23M | 7.32M | 8.74M |
| EBITDA | -22.58M | -18.96M | -25.06M | -30.58M | -233.31M |
| Net Income | -17.90M | -15.30M | -28.09M | -28.04M | -236.18M |
Balance Sheet | |||||
| Total Assets | 156.11M | 175.90M | 195.81M | 221.94M | 252.81M |
| Cash, Cash Equivalents and Short-Term Investments | 69.24M | 139.11M | 156.88M | 187.91M | 227.21M |
| Total Debt | 16.00K | 318.00K | 2.35M | 1.47M | 1.95M |
| Total Liabilities | 6.17M | 6.42M | 10.44M | 8.48M | 10.39M |
| Stockholders Equity | 149.94M | 169.48M | 185.37M | 213.46M | 242.42M |
Cash Flow | |||||
| Free Cash Flow | -10.04M | -10.32M | -26.84M | -31.81M | -33.38M |
| Operating Cash Flow | -10.00M | -10.00M | -26.13M | -30.95M | -31.49M |
| Investing Cash Flow | -877.29K | -25.91M | 5.49M | -87.57M | -1.75M |
| Financing Cash Flow | -4.60M | -1.02M | -1.46M | -572.00K | 241.82M |
Broncus Holding Corp. Technical Analysis
Negative
2.36
Price Trends
1.47
Negative
1.93
Negative
2.37
Negative
Market Momentum
-0.02
Negative
47.89
Neutral
47.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Negative. The current price of 2.36 is above the 20-day moving average (MA) of 1.27, above the 50-day MA of 1.47, and below the 200-day MA of 2.37, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.89 is Neutral, neither overbought nor oversold. The STOCH value of 47.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2216.
Broncus Holding Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$2.12B | 22.44 | 4.25% | ― | 47.07% | ― | |
53 Neutral | HK$837.92M | -0.88 | -21.05% | ― | -34.96% | 43.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$655.63M | -8.26 | -11.54% | ― | -30.60% | 28.61% | |
45 Neutral | HK$519.70M | -2.10 | -16.83% | ― | -21.90% | 5.78% | |
44 Neutral | HK$3.28B | 17.15 | 2.04% | ― | 90.81% | ― | |
43 Neutral | HK$3.29B | -4.06 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2216
Broncus Holding Corp.
1.16
-0.99
-46.05%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.47
-2.03
-45.11%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
1.90
-1.30
-40.63%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.98
1.95
32.34%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.85
-0.72
-28.02%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
54.80
28.00
104.48%
Broncus Holding Corp. Corporate Events
Broncus Holding Sets 2026 AGM, Seeks Share Issuance Mandate and Board Renewals
Apr 20, 2026
Broncus Holding Corporation has called its annual general meeting for May 14, 2026, in Hangzhou, where shareholders will review and adopt the audited consolidated financial statements for the year ended December 31, 2025, along with the directors&...
Broncus Holding Delays Shareholder Circular on Major Acquisition
Apr 14, 2026
Broncus Holding Corporation has announced a delay in sending a shareholder circular related to a major transaction involving a further acquisition of shares in a target company. The circular, which will include details of the acquisition, financia...
Broncus Deepens Lung Disease Push as Revenue Plunges on One-Off Hit
Mar 31, 2026
Broncus Holding Corporation reported a sharp downturn in 2025 revenue, largely due to a one-off sales return, which pushed the group into a gross loss and widened its annual loss despite maintaining a sizable cash position. The financial setback c...
Broncus Plans Major Stake Increase and Redirects IPO Proceeds
Mar 22, 2026
Broncus Holding Corporation has agreed, via a wholly owned subsidiary, to acquire an additional 3.85% stake in a target company for US$55.1 million, bringing the deal into the category of a major transaction under Hong Kong listing rules when aggr...
Broncus Holding Sets Date to Approve 2025 Annual Results and Consider Final Dividend
Mar 19, 2026
Broncus Holding Corporation has scheduled a board meeting for March 31, 2026 to review and approve its audited annual results for the financial year ended December 31, 2025 and to authorize their publication. The board will also consider whether t...
Broncus Details Strategic Rationale for Minority Stake in Structural Heart Device Firm
Mar 13, 2026
Broncus Holding Corporation has provided further details on its previously announced acquisition of a 1.05% equity stake in a structural heart disease-focused company, emphasizing that the minority investment is intended to deepen cooperation rath...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.